[1] Desalegn H,Aberra H,Berhe N,et al.Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa? Liver Int,2017,37(10):1461-1467. [2] Shin WG,ParkSH,JangMK,et al. Aspartate aminotransferase to platelet ratio index(APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis,2008,40(4):267-274. [3] World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection(2015,03). Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection(2015,03). http://www.who.int/hiv/pub/hepatitis-b-guidelives/en/. [4] Xiao G,Yang J,Yan L.Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection:a systemic review and meta-analysis. Hepatology,2015,61(1):292-302. [5] Lemoine M,Shimakawa Y,Nayagam S,et al.The gamma-glutamyl transpeptidase to platelet ratio(GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.Gut,2016,65:1369-1376. [6] Li Q,Song J,Huang Y,et al.The gamma-glutamyl-transpeptidase to platelet ratio?does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B:a retrospective cohort study in China. Medicine,2016,95(16):e3372. [7] Wang RQ,Zhang QS,Zhao SX,et al.Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients.J Int Med Res,2016,44(6):1302-1313. [8] Huang R,Wang G,Tian C,et al.Gamma-glutamyl-transpeptidase to platelet ratiois not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China.Sci Rep,2017,21(7):8543. [9] Ren T,Wang H,Wu R,et al.Gamma-glutamyl transpeptidase-to-platelet ratio predicts significant liver fibrosis of chronic hepatitis B patients in China.Gastroenterol Res Pract,2017,2017:7089702. [10] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ. [11] Wang H,Xue L,Yan R,et al.Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. Plos One,2013,8(11):e80585. [12] 张志侨,黄丽雯, 陈永鹏. 多项无创诊断指数评估慢性乙型肝炎肝纤维化的准确性比较.实用肝脏病杂志,2017,20(6):692-696. [13] Liu CJ,Kao JH.Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to [J]. Semin Liver Dis,2013,33(2):97-102. [14] Cao GW.Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol,2009,15(46):5761-5769. [15] Kurbanov F,Tanaka Y,Mizokami M.Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res,2010,40(1):14-30. [16] Li HM,Wang JQ,Wang R.Hepatitis B virus genotypes and genome characteristics in China. World J Gastroenterol,2015,21(21):6684-6697. [17] Federica B,Clara BC,Clara BC,et al.Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol,2014,20(40):14568-14580. [18] 胡烨,张国.肝纤维化诊断及其严重程度评估. 实用肝脏病杂志,2017,20(1):13-16. [19] 钤培国,廉晓晓,郭晓霞. 无创诊断模型诊断乙型肝炎和肝硬化患者肝纤维化价值评价.实用肝脏病杂志,2016,19(5):578-582. [20] Li Y,Cai Q,Zhang Y,et al.Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients:Significant reduction in liver biopsy. Hepatol Res,2016,46:1367-79. |